Antibiotic therapy: Resistance and surveillance methods;Antibiotikatherapie: Einfluss und methodik der surveillance

Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie

Volumn 42, Issue 2, 2007, Pages 116-121

  Meyer, Elisabeth ^a   Gastmeier, Petra ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMPICILLIN; ANTIBIOTIC AGENT; CARBAPENEM; CEFOTAXIME; CEFOTIAM; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; GLYCOPEPTIDE; IMIDAZOLE DERIVATIVE; IMIPENEM; MACROLIDE; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; SULBACTAM; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ESCHERICHIA COLI; HEALTH PROGRAM; HUMAN; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; STAPHYLOCOCCUS AUREUS; WORLD HEALTH ORGANIZATION; BACTERIAL INFECTION; EPIDEMIC; HEALTH SURVEY; INCIDENCE; INTERNATIONAL COOPERATION; METHODOLOGY; PRESCRIPTION; STATISTICS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DISEASE OUTBREAKS; DRUG RESISTANCE, BACTERIAL; HUMANS; INCIDENCE; INTERNATIONALITY; POPULATION SURVEILLANCE; PRESCRIPTIONS, DRUG;

EID: 34247129735     PISSN: 09392661     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-971163     Document Type: Review

References (8)

1. Filius PM, Liem TB, van der Linden PD, Janknegt R, Natsch S, Vulto AG, Verbrugh HA. An additional measure for quantifying antibiotic use in hospitals. J Antimicrob Chemother 2005;55:805-8
2. Meyer E, Schroeren-Boersch B, Schwab F, Jonas D, Ruden H, Gastmeier P, Daschner FD. [Quality assurance in intensive care medicine SARI-Surveillance on antibiotic use and bacterial resistance in intensive care units]. Anaesthesist 2004;53:427-33
3. Vander Stichele RH, Elseviers MM, Ferech M, Blot S, Goossens H; European Survaillance of Antibiotic Comsuption (ESAC) Project Group. Hospital consumption of antibiotics in 15 European countries: results of the ESAC Retrospective Data Collection (1997-2002). J Antimicrob Chemother. 2006;58:159-67
4. Meyer E, Schwab F, Jonas D, Rueden H, Gastmeier P, Daschner FD. Surveillance of antimicrobial use and antimicrobial resistance in intensive care units (SARI): 1. Antimicrobial use in German intensive care units. Intensive Care Med 2004;30:1089-96
5. Schwaber MJ, De Medina T, Carmeli Y. Epidemiological interpretation of antibiotic resistance studies - what are we missing? Nat Rev Microbiol 2004;2:979-83
6. Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA. Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im mitteleuropäischen Raum. 2003; Antiinfectives Intelligence, Bonn
7. Meyer E, Schwab F, Gastmeier P, Jonas D, Rueden H, Daschner FD. Methicillin-Resistant Staphylococcus aureus in German Intensive Care Units During 2000-2003: Data from Project SARI (Surveillance of Antimicrobial Use and Antimicrobial Resistance in Intensive Care Units). Infect Control Hosp Epidemiol 2006;27:146-54
8. Fridkin SK, Lawton R, Edwards JR, Tenover FC, McGowan JE, Jr., Gaynes RP. Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci. Emerg Infect Dis 2002;8:702-7